SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: roger m who wrote (8557)1/31/1999 2:10:00 AM
From: aknahow  Respond to of 17367
 
Sort of doubt that. Refer back to some of Cacaito's post. Also if and it is a if, Neuprex is approved I think they will be in a great position to negotiate partnership deals.



To: roger m who wrote (8557)1/31/1999 9:48:00 AM
From: Robert K.  Read Replies (1) | Respond to of 17367
 
Others talk the talk, xoma walks the walk. IMO >yes people are coming at them from all directions. IMO that smells success.
IMO xoma may be further ahead than most imagine.
IMO>if we get the resources>then game over.
All IMO.



To: roger m who wrote (8557)1/31/1999 6:43:00 PM
From: LarryS  Read Replies (1) | Respond to of 17367
 
"By the time any of their products are
approved other companies might leap frog
these guys."

That was your statement roger m, can you back it up? XOMA has been working on
this for years and after they announce their
success you think someone is suddenly going to appear
with the same or a better product? Name a company.
Which one?? Or, are you just a short trying to
cause a little trouble???


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News